SCHEMBL8784206

SCHEMBL8784206

CCCCOc1cccc(/C=C/C(=O)O)c1

nearest known ligand 0.76

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.76
ALDH1A1 P00352 2/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
PKM P14618 1/20 0.64
TLR4 O00206 2/20 0.63
TLR2 O60603 2/20 0.63
CYSLTR2 Q9NS75 1/20 0.55
POLB P06746 1/20 0.54
AKR1C3 P42330 1/20 0.52
BCHE P06276 3/20 0.51
APP P05067 1/20 0.51
ACHE P22303 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PLA2G4B P0C869 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8784209 1.00 KDM4E (0.76) KDM4EALDH1A1SMN1; SMN2PKMTLR4
SCHEMBL9717025 0.94 KDM4E (0.72) KDM4EALDH1A1SMN1; SMN2PKMTLR4
SCHEMBL7969956 0.94 KDM4E (0.72) KDM4EALDH1A1SMN1; SMN2PKMTLR4
SCHEMBL9717028 0.94 KDM4E (0.72) KDM4EALDH1A1SMN1; SMN2PKMTLR4
SCHEMBL7969953 0.94 KDM4E (0.72) KDM4EALDH1A1SMN1; SMN2PKMTLR4
SCHEMBL9015708 0.94 KDM4E (0.72) KDM4EALDH1A1SMN1; SMN2PKMTLR4
SCHEMBL7970157 0.94 KDM4E (0.72) KDM4EALDH1A1SMN1; SMN2PKMTLR4
SCHEMBL7970153 0.94 KDM4E (0.72) KDM4EALDH1A1SMN1; SMN2PKMTLR4
SCHEMBL28397202 0.93 KDM4E (0.78) KDM4EALDH1A1SMN1; SMN2PKMTLR4
SCHEMBL28397201 0.93 KDM4E (0.78) KDM4EALDH1A1SMN1; SMN2PKMTLR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9840515-B2 Protein kinase D inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-12-12 US disclosed
US-20160102047-A1 SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHOD AND THE USE THEREOF TOPHARMAN SHANGHAI CO., LTD. (CN) 2016-04-14 US disclosed
US-9249084-B2 Substituted n-pentanamide compounds, preparation method and the use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2016-02-02 US disclosed
US-20140045821-A1 PROTEIN KINASE D INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2014-02-13 US disclosed
US-20140046074-A1 Substituted n-pentanamide compounds, preparation method and the use thereof TOPHARMAN SHANGHAI CO., LTD. (CN) 2014-02-13 US disclosed
WO-2013090161-A1 STEREOSELECTIVE SYNTHESIS OF TAPENTADOL AND ITS SALTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 WO disclosed
US-20130150622-A1 STEREOSELECTIVE SYNTHESIS OF TAPENTADOL AND ITS SALTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 US disclosed
WO-2012078859-A2 PROTEIN KINASE D INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-06-14 WO disclosed
EP-0595995-B1 ARYLAMIDOALKYL- AND ARYLAMINOALKYL-N-HYDROXYUREA COMPOUNDS AND -N-HYDROXYFORMAMIDE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LAB (US) 1997-01-15 EP disclosed
US-5514702-A Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory activity ABBOTT LABORATORIES (US) 1996-05-07 US disclosed
EP-0595995-A4 ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LAB (US) 1994-08-24 EP disclosed
EP-0595995-A1 ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY. ABBOTT LAB (US) 1994-05-11 EP disclosed
WO-1993002037-A1 ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LABORATORIES (US) 1993-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102047-A1 SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHOD AND THE USE THEREOF PNMT, TPMT, HTR3A KDM4E 225/4885ALDH1A1 1040/4885SMN1; SMN2 476/4885
US-20140045821-A1 PROTEIN KINASE D INHIBITORS PRKCD, PRKD1, PRKD2 KDM4E 1875/4885ALDH1A1 4548/4885SMN1; SMN2 4309/4885
US-20130150622-A1 STEREOSELECTIVE SYNTHESIS OF TAPENTADOL AND ITS SALTS SLC6A2, SLC6A4, SLC6A6 KDM4E 1955/4885ALDH1A1 891/4885SMN1; SMN2 1578/4885
US-20140046074-A1 Substituted n-pentanamide compounds, preparation method and the use thereof PNMT, TPMT, HTR3A KDM4E 223/4885ALDH1A1 1012/4885SMN1; SMN2 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.